Advertisement

Archives of Dermatological Research

, Volume 311, Issue 3, pp 221–230 | Cite as

Willingness to pay and quality of life in patients with pruritic skin disorders

  • Maria Stefanidou
  • Georgios Evangelou
  • Nikolaos Kontodimopoulos
  • Dimitra KoumakiEmail author
  • Sabine-Elke Krueger-Krasagakis
  • Gil Yosipovitch
  • Konstantinos Krasagakis
Original Paper
  • 37 Downloads

Abstract

Pruritic dermatosis is a frequent and burdensome disease. The objectives of this study were (1) to assess the willingness to pay (WTP) and the health-related quality of life (HRQoL) in patients with pruritic dermatoses and (2) to compare the results with data on socio-demographic data, and clinical features/symptoms of the patients. One hundred and three patients with pruritic dermatosis had participated in a non-interventional, cross-sectional study. Socio-demographic data, clinical features/symptoms, a health-related quality of life (HRQoL)-based and a dermatology-specific instrument (SF-6D and DLQI, respectively), and two utility indicators such as rating scale (RS) and time-trade-off (TTO) as well as willingness to pay (WTP) were recorded. In our study, there was a significant correlation between DLQI scores and WTP (p < 0.001). Time-trade-off (TTO) was also statistically correlated with SF-6D (p = 0.001). Regression models showed that daily duration and pruritus intensity were associated with lower HRQoL. Furthermore, WTP was the only measure revealing demographic and socio-economic characteristics such as age, education level, family status and income as predicting factors. No significant differences between groups of varying skin diseases were observed. HRQoL and WTP proved to be valid tools to assess the burden of disease in patients with pruritic dermatosis. However, further research with a larger number of patients is needed to validate the present findings.

Keywords

Health-related quality of life SF-6D DLQI Time-trade-off Willingness to pay 

Notes

Funding

No funding has supported this work.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all the participants in this study.

Ethical approval

Ethical approval was obtained for this study.

References

  1. 1.
    Arnold D, Girling A, Stevens A, Lilford R (2009) Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis. BMJ 339:b2688.  https://doi.org/10.1136/bmj.b2688 Google Scholar
  2. 2.
    Augustin M, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Schadendorf D, Utikal J, Wagner T, Wilden S, Kähler KC (2018) Willingness to pay for a cure of low-risk melanoma patients in Germany. PLoS One 13(5):e0197780.  https://doi.org/10.1371/journal.pone.0197780. (eCollection 2018)Google Scholar
  3. 3.
    Barbier N, Paul C, Luger T et al. (2004) Validation of the eczema area and severity index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 150(1):96–102Google Scholar
  4. 4.
    Basra MKA, Fenech R, Gatt RM, Salek MS, Finley AY (2008) The Dermatology life quality index (1994–2007): a comprehensive review of validation data and clinical results. Br J Dermatol 159(5):997–1035.  https://doi.org/10.1111/j.1365-2133.2008.08832.x. (Epub 15 Sep 2008)Google Scholar
  5. 5.
    Beikert FC, Langenbruch AK, Radtke MA, Kornek T, Purwins S, Augustin M (2014) Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res 306(3):279–286.  https://doi.org/10.1007/s00403-013-1402-1 Google Scholar
  6. 6.
    Bell CM, Chapman RH, Stone PW, Sandberg EA, Neumann PJ. An off-the-shelf help list: a comprehensive catalog of preferences scores from published cost-utility analyses. Med Decis Mak 21(4):288–294Google Scholar
  7. 7.
    Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21(2):271–292Google Scholar
  8. 8.
    Chen CL, Kuppermann M, Caughey AB, Zane LT (2008) A community-based study of acne-related health preferences in adolescents. Arch Dermatol 144(8):988–994  https://doi.org/10.1001/archderm.144.8.988 Google Scholar
  9. 9.
    Dobrev HP, Atanasov NG, Dimitrova DD (2017) Implementation of Instrument based on eight health related quality of life domains for measuring of willingness to pay for psoriasis treatment. Folia Med (Plovdiv) 59(3):326–335.  https://doi.org/10.1515/folmed-2017-0041 Google Scholar
  10. 10.
    Dolan P, Gudex C, Kind P, Williams A (1996) Valuing health states: a comparison of methods. J Health Econ 15(2):209–231Google Scholar
  11. 11.
    Elman S, Hynan LS, Gabriel V, Mayo MJ (2010) The 5-D itch scale: a new measure of pruritus. Br J Dermatol 162(3):587–593.  https://doi.org/10.1111/j.1365-2133.2009.09586.x Google Scholar
  12. 12.
    Finley AY, Khan GK (1994) A simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210–216Google Scholar
  13. 13.
    Golda N, Black W, Patel V, Neal D, Etzkorn J (2019) Determining patient preferences and willingness to pay related to scar length and appearance following skin cancer treatment on the face and trunk: A multi-center discrete choice experiment. J Am Acad Dermatol  https://doi.org/10.1016/j.jaad.2019.01.080 (S0190-9622(19)30191-4)Google Scholar
  14. 14.
    Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health related quality of life. Ann Intern Med 15(8):622–629 118(Google Scholar
  15. 15.
    Hong J, Koo B, Koo J (2008) The psychosocial and occupational impact of chronic skin diseases. Dermatol Ther 21(1):54–59.  https://doi.org/10.1111/j.1529-8019.2008.00170.x Google Scholar
  16. 16.
    Kontodimopoulos N, Niakas D (2006) Overcoming inherent problems of preference-based techniques for measuring health benefits: an empirical study in the context of kidney transplantation. BMC Health Serv Res 6:3  https://doi.org/10.1186/1472-6963-6-3 Google Scholar
  17. 17.
    Krammer R, Heinzerling L (2014 Nov) Therapy preferences in melanoma treatment–willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls. PLoS One 4(11):e111237.  https://doi.org/10.1371/journal.pone.0111237 (eCollection 2014 9)Google Scholar
  18. 18.
    Kontodimopoulos N, Pappa E, Papadopoulos AA, Tountas Y, Niakas D (2009) Comparing SF-6D and EQ-5D utilities across groups differing in health status. Qual Life Res 18(1):87–97.  https://doi.org/10.1007/s11136-008-9420-8 Google Scholar
  19. 19.
    Lundberg L, Johanneson M, Silverdahl M, Hermansson C, Lindberg M (1999) Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 141(6):1067–1075Google Scholar
  20. 20.
    Majeski CL, Johnson JA, Davison SN, Lauzon GJ (2007) Itch severity scale: a self- reported instrument for the measurement of pruritus severity. Br J Dermatol 156(4):667–673Google Scholar
  21. 21.
    McFarlane PA, Pierratos A, Bayoumi AM, Redelmeier DA (2007) Estimating preference scores in conventional and home nocturnal hemodialysis patients. Clin J Am Soc Nephrol 2(3):477–483Google Scholar
  22. 22.
    O’Brien B, Gafni A (1996) When do the “dollars” make sense? Toward a conceptual framework for contigent valuation studies in health care. Med Decis Making 16:288–299Google Scholar
  23. 23.
    Radtke MA, Schäfer I, Gajur A, Langenbruch A, Augustin M (2009) Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol 161(1):134–139.  https://doi.org/10.1111/j.1365-2133.2009.09091.x Google Scholar
  24. 24.
    Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41(Pt 1):401–407 3Google Scholar
  25. 25.
    Schiffner R, Brunnberg S, Hohenleutner U, Stolz W, Landthaler M (2002) Willingness to pay and time trade-off: useful utility indicators for the assessment of quality of life and patient satisfaction in patients with port wine stains. Br J Dermatol 146(3):440–447Google Scholar
  26. 26.
    Schmitt J, Meurer M, Klon M, Frick KD (2008) Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol 158(2):351–359Google Scholar
  27. 27.
    Seidler AM, Bayoumi AM, Goldstein MK, Cruz Jr PD, Chen SC (2012) Willingness to pay in dermatology: assessment of the burden of skin diseases. J Invest Dermatol 2012 132(7):1785–1790.  https://doi.org/10.1038/jid.2012.50 Google Scholar
  28. 28.
    Senra MS, Wollenberg A (2014) Psychodermatological aspects of atopic dermatitis. Br J Dermatol 170 Suppl 1:38–43.  https://doi.org/10.1111/bjd.13084 Google Scholar
  29. 29.
    Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM (2012) Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label phase IIIB trial. Br J Dermatol 167(6):1374–1381.  https://doi.org/10.1111/bjd.12000 Google Scholar
  30. 30.
    Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wei E, Biro T (2006) Neurophysiological, neuroimmunological and neuroendocrine basis of pruritus. J Invest Dermatol 126(8):1705–1718Google Scholar
  31. 31.
    Torrance GW (1986) Measurements of health status utilities for economic appraisal: a review. J Health Econ 5(1):1–30Google Scholar
  32. 32.
    Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ (2002) Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 47(4):512–518Google Scholar
  33. 33.
    Weisshaar E, Szepietowski JC, Darsow U et al (2012) European guideline on chronic pruritus. Acta Derm Venereol 92(5):563–581.  https://doi.org/10.2340/00015555-1400 Google Scholar
  34. 34.
    Yosipovitch G, Ansari N, Goon A, Chan YH, Goh CL (2002) Clinical characteristics of pruritus in chronic idiopathic urticaria. Br J Dermatol 147:32–36Google Scholar
  35. 35.
    Zhu B, Edson-Heredia E, Guo J, Maeda-Chubachi T, Shen W, Kimball AB (2014) Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial. Br J Dermatol 171:1215–1219Google Scholar
  36. 36.
    Zug KA, Littenberg B, Baughman RD et al (1995) Assessing the preferences of patients with psoriasis. A quantitative, utility approach. Arch Dermatol 131:561–568Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Maria Stefanidou
    • 1
    • 2
  • Georgios Evangelou
    • 1
  • Nikolaos Kontodimopoulos
    • 2
  • Dimitra Koumaki
    • 1
    Email author
  • Sabine-Elke Krueger-Krasagakis
    • 1
  • Gil Yosipovitch
    • 3
  • Konstantinos Krasagakis
    • 1
  1. 1.Department of DermatologyUniversity Hospital of HeraklionCreteGreece
  2. 2.Faculty of Social SciencesHellenic Open UniversityPatraGreece
  3. 3.University of Miami, Hospital and ClinicsMiamiUSA

Personalised recommendations